Contents:

Autoimmune/Inflammatory Disease Drug Licensing Opportunities SUMMARY TABLE OF CONTENTS EXECUTIVE SUMMARY......................................................................................................................................... i SECTION 1 INTRODUCTION TO AUTOIMMUNE/INFLAMMATORY DISEASE THERAPEUTICS....... 1 1.1 SCOPE AND OBJECTIVES OF RESEARCH INVESTIGATION........................................................... 1 1.2 METHODOLOGY OF INVESTIGATION................................................................................................ 1 1.3 LIMITATIONS OF INVESTIGATION ..................................................................................................... 2 1.4 INTRODUCTION TO AUTOIMMUNE/INFLAMMATORY DISEASES AND THEIR THERAPY..... 3 SECTION 2 DELPHI PANEL AND THOUGHT LEADER INTERVIEW: DISCUSSION AND SUMMARY OF AUTOIMMUNE/INFLAMMATORY DISEASE THERAPEUTICS INNOVATION...... 7 2.1 INTRODUCTION ..................................................................................................................................... 7 2.2 RESULTS OF DELPHI PANEL INTERVIEWS....................................................................................... 7 2.3 DELPHI SUMMARY.............................................................................................................................. 30 SECTION 3 ASTHMA BUSINESS DEVELOPMENT AND INNOVATION OPPORTUNITIES .................. 33 3.1 INTRODUCTION TO THE DISEASE STATE....................................................................................... 33 3.2 INNOVATIVE ACTIVITIES UNDER WAY.......................................................................................... 36 3.3 PRODUCT TECHNOLOGY ANALYSIS AND FORECAST ................................................................ 43 3.4 MARKET ANALYSIS AND FORECAST .............................................................................................. 56 3.5 EVALUATION OF LICENSING OPPORTUNITIES – RATINGS AND RANKINGS......................... 58 SECTION 4 ATHEROSCLEROSIS BUSINESS DEVELOPMENT AND INNOVATION OPPORTUNITIES ....................................................................................................................................................... 69 4.1 INTRODUCTION TO THE DISEASE STATE....................................................................................... 69 4.2 INNOVATIVE ACTIVITIES UNDERWAY........................................................................................... 72 4.3 PRODUCT TECHNOLOGY ANALYSIS AND FORECAST ................................................................ 74 4.4 MARKET ANALYSIS AND FORECAST .............................................................................................. 80 4.5 EVALUATION OF LICENSING OPPORTUNITIES – RATINGS AND RANKINGS......................... 82 SECTION 5 TYPE I DIABETES BUSINESS DEVELOPMENT AND INNOVATION OPPORTUNITIES . 91 5.1 INTRODUCTION TO THE DISEASE STATE....................................................................................... 91 5.2 INNOVATIVE ACTIVITIES UNDER WAY.......................................................................................... 94 5.3 PRODUCT TECHNOLOGY ANALYSIS AND FORECAST ................................................................ 98 5.4 MARKET ANALYSIS AND FORECAST ............................................................................................ 104 5.5 EVALUATION OF LICENSING OPPORTUNITIES – RATINGS AND RANKINGS....................... 106 SECTION 6 INFLAMMATORY BOWEL DISEASE (CROHN’S DISEASE AND ULCERATIVE COLITIS) BUSINESS DEVELOPMENT AND INNOVATION OPPORTUNITIES............................ 111 6.1 INTRODUCTION TO THE DISEASE STATE..................................................................................... 111 6.2 INNOVATIVE ACTIVITIES UNDER WAY........................................................................................ 114 6.3 PRODUCT TECHNOLOGY ANALYSIS AND FORECAST .............................................................. 118 6.4 MARKET ANALYSIS AND FORECAST ............................................................................................ 122 6.5 EVALUATION OF LICENSING OPPORTUNITIES – RATINGS AND RANKINGS....................... 123 SECTION 7 MULTIPLE SCLEROSIS BUSINESS DEVELOPMENT AND INNOVATION OPPORTUNITIES.................................................................................................................... 127 7.1 INTRODUCTION TO THE DISEASE STATE..................................................................................... 127 7.2 INNOVATIVE ACTIVITIES UNDER WAY........................................................................................ 129 1.3 PRODUCT TECHNOLOGY ANALYSIS AND FORECAST .............................................................. 134 1.4 MARKET ANALYSIS AND FORECAST ............................................................................................ 138 1.5 EVALUATION OF LICENSING OPPORTUNITIES – RATINGS AND RANKINGS....................... 139 SECTION 8 PSORIASIS BUSINESS DEVELOPMENT AND INNOVATION OPPORTUNITIES............. 143 8.1 INTRODUCTION TO THE DISEASE STATE..................................................................................... 143 8.2 EVALUATION OF INNOVATION ACTIVITIES UNDER WAY....................................................... 144 8.3 PRODUCT TECHNOLOGY ANALYSIS AND FORECAST .............................................................. 148 8.4 MARKET ANALYSIS AND FORECAST ............................................................................................ 151 8.5 EVALUATION OF LICENSING OPPORTUNITIES – RATINGS AND RANKINGS....................... 152 SECTION 9 RHEUMATOID ARTHRITIS BUSINESS DEVELOPMENT AND INNOVATION OPPORTUNITIES.................................................................................................................... 159 9.1 INTRODUCTION TO THE DISEASE STATE..................................................................................... 159 9.2 INNOVATIVE ACTIVITIES UNDER WAY........................................................................................ 162 9.3 PRODUCT TECHNOLOGY ANALYSIS AND FORECAST .............................................................. 165 9.4 MARKET ANALYSIS AND FORECAST ............................................................................................ 170 9.5 EVALUATION OF LICENSING OPPORTUNITIES – RATINGS AND RANKINGS....................... 171 SECTION 10 SYSTEMIC LUPUS ERYTHEMATOSUS BUSINESS DEVELOPMENT AND INNOVATION OPPORTUNITIES.................................................................................................................... 181 10.1 INTRODUCTION TO THE DISEASE STATE..................................................................................... 181 10.2 INNOVATIVE ACTIVITIES UNDER WAY........................................................................................ 182 10.3 PRODUCT TECHNOLOGY ANALYSIS AND FORECAST .............................................................. 183 10.4 MARKET ANALYSIS AND FORECAST ............................................................................................ 186 10.5 EVALUATION OF LICENSING OPPORTUNITIES – RATINGS AND RANKINGS....................... 186 SECTION 11 BIOTECHNOLOGY AND DELIVERY SYSTEM COMPANIES WITH TECHNOLOGY AND RELATED INTEREST IN AUTOIMMUNE/INFLAMMATION.............................. 191 11.1 ABGENIX.............................................................................................................................................. 191 11.2 ALEXION.............................................................................................................................................. 192 11.3 ALLERGY THERAPEUTICS................................................................................................................ 193 11.4 AMYLIN................................................................................................................................................ 193 11.5 ANGIOTECH ........................................................................................................................................ 195 11.6 ARIAD................................................................................................................................................... 195 11.7 ATHEROGENICS, INC. ........................................................................................................................ 195 11.8 AVANT THERAPEUTICS .................................................................................................................... 196 11.9 AXYS..................................................................................................................................................... 197 11.10 CELGENE ............................................................................................................................................. 198 11.11 CELLTECH ........................................................................................................................................... 200 11.12 CHUGAI ................................................................................................................................................ 201 11.13 CLARION.............................................................................................................................................. 201 11.14 CONNETICS ......................................................................................................................................... 202 11.15 CORIXA ................................................................................................................................................ 203 11.16 CURIS.................................................................................................................................................... 204 11.17 DNAX.................................................................................................................................................... 205 11.18 DURA .................................................................................................................................................... 205 11.19 DYNAVAX ........................................................................................................................................... 206 11.20 EISAI ..................................................................................................................................................... 207 11.21 ELAN..................................................................................................................................................... 207 11.22 EPIGENESIS ......................................................................................................................................... 209 11.23 ESPERION............................................................................................................................................. 210 11.24 EUKARION........................................................................................................................................... 210 11.25 GENETICS INSTITUTE....................................................................................................................... 210 11.26 ICOS ...................................................................................................................................................... 211 11.27 IDEC ...................................................................................................................................................... 212 11.28 IDUN...................................................................................................................................................... 213 11.29 IMMUNE RESPONSE.......................................................................................................................... 214 11.30 IMMUNEX............................................................................................................................................ 215 11.31 INFLAZYME......................................................................................................................................... 219 11.32 INHALE THERAPEUTIC..................................................................................................................... 219 11.33 INKINE PHARMACEUTICAL COMPANY ........................................................................................ 220 11.34 GENELABS TECHNOLOGIES............................................................................................................. 220 11.35 ISIS ........................................................................................................................................................ 221 11.36 KISSEI ................................................................................................................................................... 223 11.37 LA JOLLA PHARMACEUTICALS ...................................................................................................... 224 11.38 LIGAND ................................................................................................................................................ 224 11.39 LIGOCYTE............................................................................................................................................ 225 11.40 MAGAININ........................................................................................................................................... 226 11.41 MEDAREX............................................................................................................................................ 227 11.42 MENARINI............................................................................................................................................ 227 11.43 MILLENNIUM...................................................................................................................................... 228 11.44 ML LABORATORIES ........................................................................................................................... 231 11.45 MYRIAD GENETICS ............................................................................................................................ 231 11.46 NIH ........................................................................................................................................................ 234 11.47 NEUROCRINE BIOSCIENCES ............................................................................................................ 235 11.48 NOBEX.................................................................................................................................................. 236 11.49 PEPGEN ................................................................................................................................................ 236 11.50 PIERRE FABRE.................................................................................................................................... 237 11.51 PROTEIN DESIGN LABS..................................................................................................................... 237 11.52 QUADRANT HEALTHCARE............................................................................................................... 238 11.53 REGENERON ....................................................................................................................................... 239 11.54 RESEARCH CORP. TECH.................................................................................................................... 239 11.55 SALIX PHARMACEUTICALS............................................................................................................. 240 11.56 SANKYO............................................................................................................................................... 241 11.57 SCIOS .................................................................................................................................................... 242 11.58 SEPRACOR........................................................................................................................................... 243 11.59 STEMCELLS, INC................................................................................................................................ 243 11.60 TAISHO................................................................................................................................................. 244 11.61 TEXAS BIOTECHNOLOGY................................................................................................................. 244 11.62 VASOGEN............................................................................................................................................. 246 11.63 VERTEX................................................................................................................................................ 246 11.64 XOMA ................................................................................................................................................... 247 11.65 VIVORX................................................................................................................................................ 247 DETAILED TABLE OF CONTENTS EXECUTIVE SUMMARY...............................................................................................................................................i Anti-inflammatory Therapies .........................................................................................................................................vii Immunotherapies.......................................................................................................................................................... viii Molecular Therapies..................................................................................................................................................... viii SECTION 1 INTRODUCTION TO AUTOIMMUNE/INFLAMMATORY DISEASE THERAPEUTICS....... 1 1.1 SCOPE AND OBJECTIVES OF RESEARCH INVESTIGATION........................................................... 1 1.2 METHODOLOGY OF INVESTIGATION................................................................................................ 1 1.3 LIMITATIONS OF INVESTIGATION ..................................................................................................... 2 1.4 INTRODUCTION TO AUTOIMMUNE/INFLAMMATORY DISEASES AND THEIR THERAPY..... 3 SECTION 2 DELPHI PANEL AND THOUGHT LEADER INTERVIEW: DISCUSSION AND SUMMARY OF AUTOIMMUNE/INFLAMMATORY DISEASE THERAPEUTICS INNOVATION...... 7 2.1 INTRODUCTION ..................................................................................................................................... 7 2.2 RESULTS OF DELPHI PANEL INTERVIEWS....................................................................................... 7 2.2.1 Asthma............................................................................................................................................. 7 Corticosteroids, Leukotrienes and Beta-Adrenergics ........................................................................................................7 Immunotherapies..............................................................................................................................................................9 Airway Remodeling Process ..........................................................................................................................................11 Thoughts on Future Asthma Therapy ..............................................................................................................................11 2.2.2 Atherosclerosis ............................................................................................................................... 12 2.2.3 Diabetes Type I.............................................................................................................................. 16 Diabetic Complications ..................................................................................................................................................16 Advanced Glycation End-products (A.G.E.s) and Diabetic Complications.....................................................................17 New Approaches for Insulin Therapy.............................................................................................................................18 Islet Cell Transplantation ...............................................................................................................................................19 GLP-1.............................................................................................................................................................................20 Genomics........................................................................................................................................................................20 Future Trends and Issues in Diabetes ..............................................................................................................................21 Dephi Summary..............................................................................................................................................................21 Current Therapeutic Regimens.......................................................................................................................................21 Future Treatments...........................................................................................................................................................22 2.2.4 INFLAMMATORY BOWEL DISEASE (CROHN’S DISEASE and ULCERATIVE COLITIS) and IRRITABLE BOWEL SYNDROME.................................................................................................................... 22 2.2.5 MULTIPLE SCLEROSIS................................................................................................................ 24 2.2.6 MYASTHENIA GRAVIS.................................................................................................................. 25 Unmet Needs and Difficulties ........................................................................................................................................25 Future Treatment ............................................................................................................................................................25 2.2.7 PSORIASIS .................................................................................................................................... 25 2.2.8 RHEUMATOID ARTHRITIS .......................................................................................................... 27 DMARDs and Early Treatment......................................................................................................................................27 Targeting T Cells............................................................................................................................................................27 Unmet Needs and Difficulties ........................................................................................................................................27 Change in Landscape......................................................................................................................................................28 Future Treatment ............................................................................................................................................................28 2.2.9 SYSTEMIC LUPUS ERYTHMATOSUS.......................................................................................... 28 Unmet needs and Difficulties .........................................................................................................................................28 2.3 DELPHI SUMMARY.............................................................................................................................. 30 Anti-inflammatory Therapies .........................................................................................................................................30 Immunotherapies............................................................................................................................................................31 Molecular Therapies.......................................................................................................................................................31 SECTION 3 ASTHMA BUSINESS DEVELOPMENT AND INNOVATION OPPORTUNITIES .................. 33 3.1 INTRODUCTION TO THE DISEASE STATE....................................................................................... 33 Diagnosis and Treatment................................................................................................................................................34 Asthma Medications.......................................................................................................................................................34 Long-Term-Control Medications....................................................................................................................................35 Quick-relief Medications................................................................................................................................................35 Medication Required to Maintain Control.......................................................................................................................36 3.2 INNOVATIVE ACTIVITIES UNDER WAY.......................................................................................... 36 3.3 PRODUCT TECHNOLOGY ANALYSIS AND FORECAST ................................................................ 43 Assumption Structure .....................................................................................................................................................46 Current Therapeutics ......................................................................................................................................................48 Near-term Therapeutics ..................................................................................................................................................52 Longer-term Therapeutics ..............................................................................................................................................53 3.4 MARKET ANALYSIS AND FORECAST .............................................................................................. 56 3.5 EVALUATION OF LICENSING OPPORTUNITIES – RATINGS AND RANKINGS......................... 58 SECTION 4 ATHEROSCLEROSIS BUSINESS DEVELOPMENT AND INNOVATION OPPORTUNITIES ....................................................................................................................................................... 69 4.1 INTRODUCTION TO THE DISEASE STATE....................................................................................... 69 Definition .......................................................................................................................................................................69 Etiology..........................................................................................................................................................................69 Pathophysiology .............................................................................................................................................................70 Epidemiology .................................................................................................................................................................71 Historical Treatment Patterns .........................................................................................................................................72 4.2 INNOVATIVE ACTIVITIES UNDERWAY........................................................................................... 72 4.3 PRODUCT TECHNOLOGY ANALYSIS AND FORECAST ................................................................ 74 Assumption Structure .....................................................................................................................................................78 4.4 MARKET ANALYSIS AND FORECAST .............................................................................................. 80 4.5 EVALUATION OF LICENSING OPPORTUNITIES – RATINGS AND RANKINGS......................... 82 SECTION 5 TYPE I DIABETES BUSINESS DEVELOPMENT AND INNOVATION OPPORTUNITIES . 91 5.1 INTRODUCTION TO THE DISEASE STATE....................................................................................... 91 Epidemiology .................................................................................................................................................................91 Etiology..........................................................................................................................................................................92 Pathophysiology .............................................................................................................................................................93 5.2 INNOVATIVE ACTIVITIES UNDER WAY.......................................................................................... 94 5.3 PRODUCT TECHNOLOGY ANALYSIS AND FORECAST ................................................................ 98 Assumption Structure ...................................................................................................................................................102 Longer-term Therapeutics ............................................................................................................................................104 5.4 MARKET ANALYSIS AND FORECAST ............................................................................................ 104 5.5 EVALUATION OF LICENSING OPPORTUNITIES – RATINGS AND RANKINGS....................... 106 SECTION 6 INFLAMMATORY BOWEL DISEASE (CROHN’S DISEASE AND ULCERATIVE COLITIS) BUSINESS DEVELOPMENT AND INNOVATION OPPORTUNITIES............................ 111 6.1 INTRODUCTION TO THE DISEASE STATE..................................................................................... 111 Crohn’s Disease............................................................................................................................................................112 Ulcerative Colitis..........................................................................................................................................................114 6.2 INNOVATIVE ACTIVITIES UNDER WAY........................................................................................ 114 6.3 PRODUCT TECHNOLOGY ANALYSIS AND FORECAST .............................................................. 118 6.4 MARKET ANALYSIS AND FORECAST ............................................................................................ 122 6.5 EVALUATION OF LICENSING OPPORTUNITIES – RATINGS AND RANKINGS....................... 123 SECTION 7 MULTIPLE SCLEROSIS BUSINESS DEVELOPMENT AND INNOVATION OPPORTUNITIES.................................................................................................................... 127 7.1 INTRODUCTION TO THE DISEASE STATE..................................................................................... 127 Therapies ......................................................................................................................................................................128 7.2 INNOVATIVE ACTIVITIES UNDER WAY........................................................................................ 129 7.3 PRODUCT TECHNOLOGY ANALYSIS AND FORECAST .............................................................. 134 7.4 MARKET ANALYSIS AND FORECAST ............................................................................................ 138 7.5 EVALUATION OF LICENSING OPPORTUNITIES – RATINGS AND RANKINGS....................... 139 Section 8 PSORIASIS BUSINESS DEVELOPMENT AND INNOVATION OPPORTUNITIES .................. 143 8.1 INTRODUCTION TO THE DISEASE STATE..................................................................................... 143 8.2 EVALUATION OF INNOVATION ACTIVITIES UNDER WAY....................................................... 144 8.3 PRODUCT TECHNOLOGY ANALYSIS AND FORECAST .............................................................. 148 8.4 MARKET ANALYSIS AND FORECAST ............................................................................................ 151 8.5 EVALUATION OF LICENSING OPPORTUNITIES – RATINGS AND RANKINGS....................... 152 SECTION 9 RHEUMATOID ARTHRITIS BUSINESS DEVELOPMENT AND INNOVATION OPPORTUNITIES.................................................................................................................... 159 9.1 INTRODUCTION TO THE DISEASE STATE..................................................................................... 159 9.2 INNOVATIVE ACTIVITIES UNDER WAY........................................................................................ 162 9.3 PRODUCT TECHNOLOGY ANALYSIS AND FORECAST .............................................................. 165 9.4 MARKET ANALYSIS AND FORECAST ............................................................................................ 170 9.5 EVALUATION OF LICENSING OPPORTUNITIES – RATINGS AND RANKINGS....................... 171 SECTION 10 SYSTEMIC LUPUS ERYTHEMATOSUS BUSINESS DEVELOPMENT AND INNOVATION OPPORTUNITIES.................................................................................................................... 181 10.1 INTRODUCTION TO THE DISEASE STATE..................................................................................... 181 Diagnosis......................................................................................................................................................................181 Therapy ........................................................................................................................................................................182 10.2 INNOVATIVE ACTIVITIES UNDER WAY........................................................................................ 182 10.3 PRODUCT TECHNOLOGY ANALYSIS AND FORECAST .............................................................. 183 10.4 MARKET ANALYSIS AND FORECAST ............................................................................................ 186 10.5 EVALUATION OF LICENSING OPPORTUNITIES – RATINGS AND RANKINGS....................... 186 SECTION 11 BIOTECHNOLOGY AND DELIVERY SYSTEM COMPANIES WITH TECHNOLOGY AND RELATED INTEREST IN AUTOIMMUNE/INFLAMMATION.............................. 191 11.1 ABGENIX.............................................................................................................................................. 191 11.2 ALEXION.............................................................................................................................................. 192 11.3 ALLERGY THERAPEUTICS................................................................................................................ 193 11.4 AMYLIN................................................................................................................................................ 193 11.5 ANGIOTECH ........................................................................................................................................ 195 11.6 ARIAD................................................................................................................................................... 195 11.7 ATHEROGENICS, INC. ........................................................................................................................ 195 11.8 AVANT THERAPEUTICS .................................................................................................................... 196 11.9 AXYS..................................................................................................................................................... 197 11.10 CELGENE ............................................................................................................................................. 198 11.11 CELLTECH ........................................................................................................................................... 200 11.12 CHUGAI ................................................................................................................................................ 201 11.13 CLARION.............................................................................................................................................. 201 11.14 CONNETICS ......................................................................................................................................... 202 11.15 CORIXA ................................................................................................................................................ 203 11.16 CURIS.................................................................................................................................................... 204 11.17 DNAX.................................................................................................................................................... 205 11.18 DURA .................................................................................................................................................... 205 11.19 DYNAVAX ........................................................................................................................................... 206 11.20 EISAI ..................................................................................................................................................... 207 11.21 ELAN..................................................................................................................................................... 207 11.22 EPIGENESIS ......................................................................................................................................... 209 11.23 ESPERION............................................................................................................................................. 210 11.24 EUKARION........................................................................................................................................... 210 11.25 GENETICS INSTITUTE....................................................................................................................... 210 11.26 ICOS ...................................................................................................................................................... 211 11.27 IDEC ...................................................................................................................................................... 212 11.28 IDUN...................................................................................................................................................... 213 11.29 IMMUNE RESPONSE.......................................................................................................................... 214 11.30 IMMUNEX............................................................................................................................................ 215 11.31 INFLAZYME......................................................................................................................................... 219 11.32 INHALE THERAPEUTIC..................................................................................................................... 219 11.33 INKINE PHARMACEUTICAL COMPANY ........................................................................................ 220 11.34 GENELABS TECHNOLOGIES............................................................................................................. 220 11.35 ISIS ........................................................................................................................................................ 221 11.36 KISSEI ................................................................................................................................................... 223 11.37 LA JOLLA PHARMACEUTICALS ...................................................................................................... 224 11.38 LIGAND ................................................................................................................................................ 224 11.39 LIGOCYTE............................................................................................................................................ 225 11.40 MAGAININ........................................................................................................................................... 226 11.41 MEDAREX............................................................................................................................................ 227 11.42 MENARINI............................................................................................................................................ 227 11.43 MILLENNIUM...................................................................................................................................... 228 11.44 ML LABORATORIES ........................................................................................................................... 231 11.45 MYRIAD GENETICS ............................................................................................................................ 231 11.46 NIH ........................................................................................................................................................ 234 11.47 NEUROCRINE BIOSCIENCES ............................................................................................................ 235 11.48 NOBEX.................................................................................................................................................. 236 11.49 PEPGEN ................................................................................................................................................ 236 11.50 PIERRE FABRE.................................................................................................................................... 237 11.51 PROTEIN DESIGN LABS..................................................................................................................... 237 11.52 QUADRANT HEALTHCARE............................................................................................................... 238 11.53 REGENERON ....................................................................................................................................... 239 11.54 RESEARCH CORP. TECH.................................................................................................................... 239 11.55 SALIX PHARMACEUTICALS............................................................................................................. 240 11.56 SANKYO............................................................................................................................................... 241 11.57 SCIOS .................................................................................................................................................... 242 11.58 SEPRACOR........................................................................................................................................... 243 11.59 STEMCELLS, INC................................................................................................................................ 243 11.60 TAISHO................................................................................................................................................. 244 11.61 TEXAS BIOTECHNOLOGY................................................................................................................. 244 11.62 VASOGEN............................................................................................................................................. 246 11.63 VERTEX................................................................................................................................................ 246 11.64 XOMA ................................................................................................................................................... 247 11.65 VIVORX................................................................................................................................................ 247 LIST OF FIGURES Figure 3.1 Market Impact Matrix for Technology Platforms in Asthma Therapy ................. 46 Figure 3.2 WW Forecast for Asthma Therapy by Technology Platform ............................... 47 Figure 4.1 Market Impact Matrix for Technology Platforms in Atherosclerosis Therapy..... 77 Figure 4.2 WW Forecast for Atherosclerosis Therapy by Technology Platform................... 78 Figure 5.1 Market Impact Matrix for Technology Platforms in Type I Diabetes Therapy.. 100 Figure 5.2 WW Forecast for Type I Diabetes Therapy by Technology Platform ................ 101 Figure 5.3 US Forecast for Insulin Delivery Platforms........................................................ 102 Figure 6.1 Market Impact Matrix for Technology Platforms in Inflammatory Bowel Therapy................................................................................................................ 120 Figure 6.2 WW Forecast for Inflammatory Bowel Therapy by Technology Platform ........ 121 Figure 7.1 Market Impact Matrix for Technology Platforms in Multiple Sclerosis Therapy................................................................................................................ 136 Figure 7.2 WW Forecast for Multiple Sclerosis Therapy by Technology Platform ............ 137 Figure 8.1 Market Impact Matrix for Technology Platforms in Psoriasis Therapy ............. 149 Figure 8.2 WW Forecast for Psoriasis Therapy by Technology Platform ........................... 150 Figure 9.1 Market Impact Matrix for Technology Platforms in Rheumatoid Arthritis Therapy................................................................................................................ 168 Figure 9.2 WW Forecast for Rheumatoid Arthritis Therapy by Technology Platform........ 169 Figure 10.1 Market Impact Matrix for Technology Platforms in Lupus Erythmatosus......... 184 Figure 10.2 WW Forecast for Lupus Erythmatosus Therapy by Technology Platform......... 185 LIST OF TABLES Table 3.1 Product Development Activity for Asthma Therapy by Phase of Development .. 45 Table 3.2 US Market Forecast for Asthma Therapy by Technology .................................... 58 Table 3.3 Opportunity Sorting Matrix for Asthma Therapy ................................................. 59 Table 3.4 Product Development Activity for Asthma Therapy ........................................... 62 Table 4.1 Product Development Activity for Atherosclerosis Therapy by Phase of Development ......................................................................................................... 76 Table 4.2 US Market Forecast for Atherosclerosis Therapy by Technology........................ 81 Table 4.3 Opportunity Sorting Matrix for Atherosclerosis Therapy..................................... 83 Table 4.4 Product Development Activity for Atherosclerosis Therapy................................ 87 Table 5.1 Product Development Activity for Type I Diabetes Therapy by Phase of Development ......................................................................................................... 99 Table 5.2 US Market Forecast for Type I Diabetes Therapy by Technology..................... 106 Table 5.3 Opportunity Sorting Matrix for Type I Diabetes Therapy .................................. 107 Table 5.4 Product Development Activity for Diabetes Therapy......................................... 109 Table 6.1 Product Development Activity for Inflammatory Bowel Therapy by Phase of Development ....................................................................................................... 119 Table 6.2 US Market Forecast for Inflammatory Bowel Therapy by Technology ............. 122 Table 6.3 Opportunity Sorting Matrix for Inflammatory Bowel Disease Therapy............. 124 Table 6.4 Product Development Activity for Inflammatory Bowel Disease Therapy........ 125 Table 7.1 Product Development Activity for Multiple Sclerosis Therapy by Phase of Development ....................................................................................................... 135 Table 7.2 US Market Forecast for Multiple Sclerosis Therapy by Technology ................. 139 Table 7.3 Opportunity Sorting Matrix for Multiple Sclerosis Therapy .............................. 140 Table 7.4 Product Development Activity for Multiple Sclerosis Therapy.......................... 141 Table 8.1 Product Development Activity for Psoriasis Therapy by Phase of Development ....................................................................................................... 148 Table 8.2 US Market Forecast for Psoriasis Therapy by Technology ................................ 152 Table 8.3 Opportunity Sorting Matrix for Psoriasis Therapy ............................................. 153 Table 8.4 Product Development Activity for Psoriasis Therapy......................................... 156 Table 9.1 Product Development Activity for Rheumatoid Arthritis Therapy by Phase of Development ....................................................................................................... 167 Table 9.2 US Market Forecast for Rheumatoid Arthritis Therapy by Technology ............ 171 Table 9.3 Opportunity Sorting Matrix for Rheumatoid Arthritis Therapy.......................... 173 Table 9.4 Product Development Activity for Rheumatoid Arthritis Therapy..................... 176 Table 10.1 Product Development Activity for Lupus Erythmatosus Therapy by Phase of Development ....................................................................................................... 183 ©2001 Adis International, Inc, The Genesis Group. May not be reproduced without written permission.. Table 10.2 US Market Forecast for Systemic Lupus Erythematosus Therapy by Technology.......................................................................................................... 186 Table 10.3 Opportunity Sorting Matrix for Systemic Lupus Erythematosus Therapy ......... 188 Table 10.4 Product Development Activity for Systemic Lupus Erythematosus Therapy .... 189

Summary:

This report is designed to provide a useful tool to professionals in research and development (R&D), marketing, business development, licensing, and strategic planning who are, or are anticipating, involvement in the discovery, development, licensing, and/or marketing of therapeutics for the treatment of autoimmune and inflammatory diseases.